Anti-CD32B

CD32B (also known as FCγRIIb), a type I transmembrane receptor with low affinity for monomeric IgG, is a critical regulatory element in B-cell homeostasis.  Expressed on a variety of hematopoietic cell types including B cells, dendritic cells, monocytes/macrophages, basophils and mast cells, CD32B controls the threshold and extent of cell activation by counterbalancing the stimulatory activity of a variety of receptors. Based upon the unique function and expression pattern of CD32B, MacroGenics is developing multiple anti-CD32B products, which include cell depleting, functional and adjuvant strategies. An IND for the first anti-CD32B product is anticipated to be filed in 2008 for the treatment of B cell malignancies.